LT3689865T - Nauji aminopirimidinų dariniai - Google Patents

Nauji aminopirimidinų dariniai

Info

Publication number
LT3689865T
LT3689865T LTEP20158961.1T LT20158961T LT3689865T LT 3689865 T LT3689865 T LT 3689865T LT 20158961 T LT20158961 T LT 20158961T LT 3689865 T LT3689865 T LT 3689865T
Authority
LT
Lithuania
Prior art keywords
aminopyrimidine derivatives
new
new aminopyrimidine
derivatives
aminopyrimidine
Prior art date
Application number
LTEP20158961.1T
Other languages
English (en)
Inventor
Daniela Angst
Francois Gessier
Anna Vulpetti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT3689865T publication Critical patent/LT3689865T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LTEP20158961.1T 2013-11-29 2014-11-28 Nauji aminopirimidinų dariniai LT3689865T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13195081 2013-11-29

Publications (1)

Publication Number Publication Date
LT3689865T true LT3689865T (lt) 2023-07-10

Family

ID=49674216

Family Applications (3)

Application Number Title Priority Date Filing Date
LTEP14821285.5T LT3074386T (lt) 2013-11-29 2014-11-28 Nauji aminopirimidino dariniai
LTEP20158961.1T LT3689865T (lt) 2013-11-29 2014-11-28 Nauji aminopirimidinų dariniai
LTEP17191467.4T LT3299368T (lt) 2013-11-29 2014-11-28 Nauji aminopirimidino dariniai

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP14821285.5T LT3074386T (lt) 2013-11-29 2014-11-28 Nauji aminopirimidino dariniai

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP17191467.4T LT3299368T (lt) 2013-11-29 2014-11-28 Nauji aminopirimidino dariniai

Country Status (42)

Country Link
US (6) US9512084B2 (lt)
EP (5) EP3689865B1 (lt)
JP (2) JP6342495B2 (lt)
KR (2) KR102380539B1 (lt)
CN (2) CN110172056B (lt)
AP (1) AP2016009158A0 (lt)
AR (1) AR098549A1 (lt)
AU (1) AU2014356069B2 (lt)
BR (1) BR112016010397B1 (lt)
CA (1) CA2926908C (lt)
CL (1) CL2016001055A1 (lt)
CR (1) CR20160244A (lt)
CU (1) CU24384B1 (lt)
CY (3) CY1119705T1 (lt)
DK (3) DK3689865T3 (lt)
EA (1) EA031218B1 (lt)
EC (1) ECSP16054826A (lt)
ES (4) ES2947770T3 (lt)
FI (1) FI3689865T3 (lt)
HR (3) HRP20230585T1 (lt)
HU (3) HUE062248T2 (lt)
IL (1) IL244943B (lt)
JO (1) JO3314B1 (lt)
LT (3) LT3074386T (lt)
MA (1) MA39055B1 (lt)
MX (1) MX367911B (lt)
MY (2) MY179059A (lt)
NO (1) NO3074386T3 (lt)
NZ (1) NZ718835A (lt)
PE (1) PE20160869A1 (lt)
PH (1) PH12016500791B1 (lt)
PL (3) PL3299368T3 (lt)
PT (3) PT3299368T (lt)
RS (3) RS60251B1 (lt)
SI (3) SI3689865T1 (lt)
SV (1) SV2016005206A (lt)
TN (1) TN2016000128A1 (lt)
TW (1) TWI652261B (lt)
UA (1) UA117256C2 (lt)
UY (1) UY35858A (lt)
WO (1) WO2015079417A1 (lt)
ZA (1) ZA201602275B (lt)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
IL322264A (en) 2014-04-07 2025-09-01 Novartis Ag Cancer treatment using chimeric antigen receptor (CAR) against CD19
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
MY181834A (en) 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US20170209492A1 (en) 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
SG11201700770PA (en) 2014-08-19 2017-03-30 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
ES2891332T3 (es) 2014-09-17 2022-01-27 Novartis Ag Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
AU2015330898B2 (en) 2014-10-08 2022-03-10 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
EP3280795B1 (en) * 2015-04-07 2021-03-24 Novartis AG Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
PT3393504T (pt) 2015-12-22 2025-12-30 Novartis Ag Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
CA3016287A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
CN109641947B (zh) 2016-07-20 2023-04-14 犹他大学研究基金会 Cd229 car t细胞及其使用方法
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
US20200078400A1 (en) 2016-12-03 2020-03-12 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN111225675B (zh) 2017-06-02 2024-05-03 朱诺治疗学股份有限公司 使用过继细胞疗法治疗的制品和方法
EP3644721A1 (en) 2017-06-29 2020-05-06 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
MX2020004572A (es) 2017-11-01 2020-10-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos.
CA3080904A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
AR113796A1 (es) * 2017-11-06 2020-06-10 Lilly Co Eli Compuestos inhibidores de tirosina cinasa de bruton (btk)
KR20200116081A (ko) 2017-12-01 2020-10-08 주노 쎄러퓨티크스 인코퍼레이티드 유전자 조작된 세포의 투약 및 조절 방법
CN108069911A (zh) * 2017-12-14 2018-05-25 中国药科大学 6－氨基－2－苯基嘧啶类化合物、制备方法和医药用途
WO2019118937A1 (en) 2017-12-15 2019-06-20 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
AU2019284911B2 (en) 2018-06-13 2026-04-09 Novartis Ag BCMA chimeric antigen receptors and uses thereof
US12168012B2 (en) 2018-07-25 2024-12-17 Novartis Ag NLRP3 inflammasome inhibitors
CN120904205A (zh) 2018-08-29 2025-11-07 安塞塔制药公司 制备阿卡拉布替尼的方法
SG11202104188VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
MX2021005022A (es) 2018-11-01 2021-09-08 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d).
EP3880238A1 (en) 2018-11-16 2021-09-22 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
BR112021010354A2 (pt) 2018-11-30 2021-11-03 Juno Therapeutics Inc Métodos para o tratamento usando terapia celular adotiva
CA3123303A1 (en) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
WO2020234780A1 (en) 2019-05-23 2020-11-26 Novartis Ag Methods of treating asthma using a bruton's tyrosine kinase inhibitor
BR112021023110A2 (pt) * 2019-05-23 2022-04-12 Novartis Ag Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
EP4599894A3 (en) 2019-05-23 2025-11-12 Novartis AG Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor
MX2021014157A (es) * 2019-05-23 2022-01-04 Novartis Ag Formas cristalinas de un inhibidor btk.
JP7646671B2 (ja) * 2019-12-23 2025-03-17 バイオジェン・エムエイ・インコーポレイテッド Ｂｔｋ阻害剤
IL297147B1 (en) 2020-04-10 2026-05-01 Juno Therapeutics Inc Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen
WO2022033569A1 (zh) * 2020-08-14 2022-02-17 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物的晶型及其制备方法
CN116157404B (zh) 2020-08-14 2025-10-14 诺华股份有限公司 杂芳基取代的螺哌啶基衍生物及其药物用途
CN116782888A (zh) * 2021-01-26 2023-09-19 诺华股份有限公司 药物组合物
MX2023008671A (es) 2021-01-26 2023-09-25 Novartis Ag Composicion farmaceutica.
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2023031840A1 (en) 2021-09-03 2023-03-09 Novartis Ag Lou064 for treating multiple sclerosis
IL313079A (en) 2021-12-14 2024-07-01 Novartis Ag Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
CN120051298A (zh) 2022-08-05 2025-05-27 朱诺治疗学股份有限公司 Gprc5d和bcma特异性嵌合抗原受体
KR20250079180A (ko) 2022-09-30 2025-06-04 노파르티스 아게 레미브루티닙의 제조를 위한 합성 방법 및 중간체
WO2024129778A2 (en) 2022-12-13 2024-06-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
TW202515850A (zh) * 2023-09-22 2025-04-16 大陸商江蘇恆瑞醫藥股份有限公司 雜芳基類化合物、其製備方法及其在醫藥上的應用
CN117024354B (zh) * 2023-10-08 2023-12-08 天津凯莱英制药有限公司 瑞米布替尼的制备方法
US20250243170A1 (en) 2024-01-26 2025-07-31 Novartis Ag Remibrutinib drug substance and drug product substantially free of nitrosamine impurity
TW202602859A (zh) 2024-04-02 2026-01-16 瑞士商諾華公司 製備基本上不含亞硝胺雜質的瑞布替尼之方法
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
CA2426508A1 (en) 2000-10-23 2002-05-16 Bristol-Myers Squibb Company Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states
SG159378A1 (en) 2000-11-07 2010-03-30 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
PE20040079A1 (es) 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
EP1576137A4 (en) 2002-10-29 2010-06-30 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
WO2004052359A1 (en) 2002-12-09 2004-06-24 The Board Of Regents Of The University Of Texas System Methods for selectively inhibiting janus tyrosine kinase 3 (jak3)
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
AU2004251146A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
US20080207613A1 (en) 2004-01-12 2008-08-28 Cytopia Research Pty Ltd Selective Kinase Inhibitors
WO2006099075A2 (en) 2005-03-10 2006-09-21 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
JP2010502751A (ja) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
PL2526933T3 (pl) 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
CA2680589A1 (en) 2007-03-14 2008-09-18 Universita' Degli Studi Di Milano - Bicocca Modulator compounds of the drug resistance in epithelial tumour cells
JP5529852B2 (ja) 2008-05-06 2014-06-25 ジリード コネティカット，インコーポレイティド 置換アミド、その製造法及びＢｔｋインヒビターとしての使用
CA2728683C (en) 2008-07-02 2017-05-02 F.Hoffmann-La Roche Ag Novel phenylpyrazinones as kinase inhibitors
CA2730930C (en) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
US20100261776A1 (en) 2008-11-07 2010-10-14 The Research Foundation Of State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
EP2421854B1 (en) 2009-04-24 2014-07-23 F.Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
AR080328A1 (es) * 2010-02-26 2012-03-28 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
US8703767B2 (en) 2011-04-01 2014-04-22 University Of Utah Research Foundation Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors
HUE048834T2 (hu) 2011-05-17 2020-08-28 Univ California Kináz inhibitorok
EA031153B1 (ru) 2011-06-10 2018-11-30 Мерк Патент Гмбх Применение пиримидиновых соединений с btk ингибирующей активностью
BR112013033534A2 (pt) 2011-06-28 2017-02-07 Pharmacyclics Inc métodos e composições para inibição de reabsorção de osso
KR20140058543A (ko) 2011-07-08 2014-05-14 노파르티스 아게 신규 피롤로 피리미딘 유도체
EP3778896A1 (en) 2011-08-09 2021-02-17 Fred Hutchinson Cancer Research Center Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
CN110801454A (zh) 2011-10-19 2020-02-18 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的用途
JP2014532658A (ja) 2011-10-28 2014-12-08 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ブルトン型チロシンキナーゼ疾患または障害を治療する方法
JP5832664B2 (ja) 2011-12-09 2015-12-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトン型チロシンキナーゼの阻害剤
CN104169260A (zh) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 新三嗪衍生物
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
WO2013157022A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
WO2013173518A1 (en) 2012-05-16 2013-11-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
MA37830B1 (fr) 2012-08-10 2018-09-28 Boehringer Ingelheim Int Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)
CA2887435A1 (en) 2012-10-04 2014-04-10 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives

Also Published As

Publication number Publication date
ES2947770T3 (es) 2023-08-18
PE20160869A1 (es) 2016-09-08
KR102380539B1 (ko) 2022-03-29
HRP20171999T1 (hr) 2018-02-09
HUE062248T2 (hu) 2023-10-28
CU24384B1 (es) 2019-03-04
EP3074386A1 (en) 2016-10-05
FI3689865T3 (fi) 2023-06-12
ZA201602275B (en) 2017-08-30
EP3689865B1 (en) 2023-03-29
HRP20200775T1 (hr) 2020-07-24
EP3074386B1 (en) 2017-10-11
TW201609666A (zh) 2016-03-16
KR102421388B1 (ko) 2022-07-18
PT3689865T (pt) 2023-06-16
WO2015079417A1 (en) 2015-06-04
CY1122924T1 (el) 2021-10-29
MA39055A1 (fr) 2018-02-28
PL3689865T3 (pl) 2023-07-31
CN110172056A (zh) 2019-08-27
EP3689865A1 (en) 2020-08-05
JO3314B1 (ar) 2019-03-13
JP6667573B2 (ja) 2020-03-18
TN2016000128A1 (en) 2017-10-06
US10457647B2 (en) 2019-10-29
US20230312483A1 (en) 2023-10-05
ES2791525T3 (es) 2020-11-04
SI3689865T1 (sl) 2023-07-31
SI3074386T1 (en) 2018-02-28
CR20160244A (es) 2016-07-29
AU2014356069A1 (en) 2016-05-05
AR098549A1 (es) 2016-06-01
MY191381A (en) 2022-06-22
HUE037588T2 (hu) 2018-09-28
DK3074386T3 (en) 2018-01-22
EP3299368B1 (en) 2020-02-26
US20200010426A1 (en) 2020-01-09
CY1126056T1 (el) 2023-11-15
MA39055B1 (fr) 2018-10-31
HK1223368A1 (en) 2017-07-28
JP6342495B2 (ja) 2018-06-13
CA2926908C (en) 2021-10-26
HRP20230585T1 (hr) 2023-09-01
IL244943B (en) 2020-04-30
US20220041561A1 (en) 2022-02-10
CU20160078A7 (es) 2016-09-30
PH12016500791A1 (en) 2016-06-13
JP2018141005A (ja) 2018-09-13
CN105683181B (zh) 2019-04-23
US9512084B2 (en) 2016-12-06
MX367911B (es) 2019-09-11
DK3689865T3 (en) 2023-06-19
RS64275B1 (sr) 2023-07-31
IL244943A0 (en) 2016-05-31
KR20160088877A (ko) 2016-07-26
CA2926908A1 (en) 2015-06-04
ES3040769T3 (en) 2025-11-04
US20180251432A1 (en) 2018-09-06
RS60251B1 (sr) 2020-06-30
UY35858A (es) 2015-06-30
BR112016010397A8 (pt) 2020-04-22
SI3299368T1 (sl) 2020-07-31
US20160235746A1 (en) 2016-08-18
LT3299368T (lt) 2020-05-25
PT3299368T (pt) 2020-05-28
CN105683181A (zh) 2016-06-15
US11673868B2 (en) 2023-06-13
NO3074386T3 (lt) 2018-03-10
LT3074386T (lt) 2017-12-27
EA201691125A1 (ru) 2016-09-30
EP4219478B1 (en) 2025-06-11
BR112016010397B1 (pt) 2023-04-11
MY179059A (en) 2020-10-26
HUE049794T2 (hu) 2020-10-28
MX2016006908A (es) 2016-08-17
EP3299368A1 (en) 2018-03-28
AP2016009158A0 (en) 2016-04-30
ES2655527T3 (es) 2018-02-20
PL3074386T3 (pl) 2018-03-30
US11180460B2 (en) 2021-11-23
KR20220044370A (ko) 2022-04-07
SV2016005206A (es) 2016-11-21
RS56657B1 (sr) 2018-03-30
TWI652261B (zh) 2019-03-01
CN110172056B (zh) 2022-04-19
CY1119705T1 (el) 2018-06-27
JP2016538313A (ja) 2016-12-08
UA117256C2 (uk) 2018-07-10
PT3074386T (pt) 2017-11-15
EP4606377A2 (en) 2025-08-27
PL3299368T3 (pl) 2020-08-10
EA031218B1 (ru) 2018-12-28
ECSP16054826A (es) 2017-10-31
NZ718835A (en) 2021-12-24
PH12016500791B1 (en) 2016-06-13
HK1252317A1 (en) 2019-05-24
EP4219478A1 (en) 2023-08-02
DK3299368T3 (da) 2020-05-25
CL2016001055A1 (es) 2016-10-28
EP4606377A3 (en) 2025-11-26
US20150152068A1 (en) 2015-06-04
AU2014356069B2 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
FIC20240001I1 (fi) Tislelitsumabi
NO2023037I1 (no) Mirikizumab
HUE049794T2 (hu) Új aminopirimidin származékok
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
HRP20181334T1 (hr) Samohodno plovilo
HUE037097T2 (hu) Hõszigetelõpanel
DK3077047T3 (da) Aramcholsalte
DK3052081T3 (da) Pastil
DK3060460T3 (da) Saddel
UY4325S (es) Otomana
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK2956698T3 (da) Bindestrimler
DK2952513T3 (da) Azolbenzenderivat
PL2945641T3 (pl) Cykloalkinowe pochodne sacharydów
EP2943489A4 (en) DEUTERATED MOMELOTINIB
DK2946640T3 (da) Langmuir-probe
DE102013106534B8 (de) Chromatographiepipettenspitze
EP2991647A4 (en) DEUTERED AMLEXANOX
EP2970310A4 (en) 5-BROMO-indirubins
EP2853297A4 (en) kendama
DK3071227T3 (da) Fiskevaccine
EP3047192A4 (en) LOCKABLE LOCATED CONNECTOR
DE112014001252A5 (de) Aufbissschiene
DK3086679T3 (da) Sportssko